NASDAQ:ALXO ALX Oncology (ALXO) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free ALXO Stock Alerts $11.15 -0.26 (-2.28%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$10.60▼$11.4550-Day Range$10.95▼$16.7952-Week Range$3.94▼$17.42Volume1.18 million shsAverage Volume445,628 shsMarket Capitalization$559.17 millionP/E RatioN/ADividend YieldN/APrice Target$18.42 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ALX Oncology alerts: Email Address ALX Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside65.2% Upside$18.42 Price TargetShort InterestHealthy10.70% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.23Based on 6 Articles This WeekInsider TradingAcquiring Shares$49,764 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($3.33) to ($2.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.55 out of 5 starsMedical Sector305th out of 939 stocksPharmaceutical Preparations Industry142nd out of 444 stocks 3.4 Analyst's Opinion Consensus RatingALX Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.42, ALX Oncology has a forecasted upside of 65.2% from its current price of $11.15.Amount of Analyst CoverageALX Oncology has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.70% of the float of ALX Oncology has been sold short.Short Interest Ratio / Days to CoverALX Oncology has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in ALX Oncology has recently decreased by 16.38%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldALX Oncology does not currently pay a dividend.Dividend GrowthALX Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALXO. Previous Next 2.9 News and Social Media Coverage News SentimentALX Oncology has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for ALX Oncology this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for ALXO on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ALX Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ALX Oncology insiders have bought 34.68% more of their company's stock than they have sold. Specifically, they have bought $49,764.00 in company stock and sold $36,951.00 in company stock.Percentage Held by Insiders50.30% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.97% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ALX Oncology are expected to grow in the coming year, from ($3.33) to ($2.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ALX Oncology is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ALX Oncology is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioALX Oncology has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About ALX Oncology Stock (NASDAQ:ALXO)ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Read More ALXO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALXO Stock News HeadlinesMarch 19, 2024 | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) CEO Jason Lettmann Acquires 4,400 SharesMarch 24, 2024 | americanbankingnews.comALX Oncology (NASDAQ:ALXO) Shares Gap Down to $12.51March 29, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 23, 2024 | americanbankingnews.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Recommendation of "Moderate Buy" from BrokeragesMarch 20, 2024 | investing.comAlx Oncology CEO buys $49.7k in company sharesMarch 20, 2024 | americanbankingnews.comALX Oncology (NASDAQ:ALXO) Shares Gap Up on Insider Buying ActivityMarch 17, 2024 | finance.yahoo.comALXO Apr 2024 7.000 putMarch 16, 2024 | finance.yahoo.comALXO Apr 2024 14.000 putMarch 29, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 16, 2024 | finance.yahoo.comALXO Apr 2024 19.000 callMarch 8, 2024 | markets.businessinsider.comALX Oncology’s Evorpacept Shows Promising Potential in Cancer Treatment StudiesMarch 8, 2024 | markets.businessinsider.comALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric CancerMarch 8, 2024 | realmoney.thestreet.comALX Oncology just downgraded at Stifel, here's whyMarch 8, 2024 | finance.yahoo.comALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D SpendingMarch 8, 2024 | investorplace.comALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q4 2023March 7, 2024 | globenewswire.comALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 5, 2024 | globenewswire.comALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual MeetingFebruary 15, 2024 | wsj.comALX Oncology Holdings Inc.February 9, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Haemonetics (HAE), ALX Oncology Holdings (ALXO)December 22, 2023 | seekingalpha.comALX Oncology: Major Caution Warranted Moving ForwardDecember 16, 2023 | msn.comAlx Oncology Holdings (ALXO) Price Target Increased by 10.93% to 17.26December 9, 2023 | msn.comJefferies Upgrades Alx Oncology Holdings (ALXO)December 8, 2023 | msn.comJefferies raises ALX Oncology to buy, cites upcoming catalystsDecember 8, 2023 | msn.comALX Oncology shares jump 9% after Jefferies upgradeNovember 15, 2023 | markets.businessinsider.comPromising Interim Data and Financial Stability Prompt Buy Rating for ALX Oncology HoldingsNovember 13, 2023 | finance.yahoo.comALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 13, 2023 | finance.yahoo.comALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate DevelopmentsSee More Headlines Receive ALXO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALXO CUSIPN/A CIK1810182 Webwww.alxoncology.com Phone650-466-7125FaxN/AEmployees72Year FoundedN/APrice Target and Rating Average Stock Price Target$18.42 High Stock Price Target$27.00 Low Stock Price Target$11.00 Potential Upside/Downside+65.2%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.10% Return on Assets-62.59% Debt Debt-to-Equity Ratio0.05 Current Ratio5.24 Quick Ratio5.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.81 per share Price / Book2.93Miscellaneous Outstanding Shares50,150,000Free Float24,926,000Market Cap$559.17 million OptionableOptionable Beta1.63 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Corey S. Goodman Ph.D. (Age 72)Executive Chairman Comp: $84kMr. Jason W. Lettmann (Age 47)CEO & Director Comp: $60.5kDr. Jaume Pons Ph.D. (Age 57)Founder, President, Director & Chief Scientific Officer Comp: $856.29kMr. Peter S. Garcia M.B.A. (Age 62)Chief Financial Officer Comp: $631.11kDr. Sophia Randolph M.D. (Age 56)Ph.D., Chief Medical Officer & Director Comp: $637.24kDr. Michael Chang Ph.D.Vice President of OperationsMs. Shelly Pinto (Age 47)Senior VP of Finance & Chief Accounting Officer Comp: $508.26kDr. Christopher Byrd J.D.Ph.D., General CounselDr. Athanasios Tsiatis M.D.Senior Vice President of Clinical DevelopmentDr. Lin Yeong-Liang M.D.M.S., Senior Vice President of Drug Safety & PharmacovigilanceMore ExecutivesKey CompetitorsFulcrum TherapeuticsNASDAQ:FULCArriVent BioPharmaNASDAQ:AVBPTravere TherapeuticsNASDAQ:TVTXCOMPASS PathwaysNASDAQ:CMPSGH ResearchNASDAQ:GHRSView All CompetitorsInsiders & InstitutionsJason LettmannBought 4,400 shares on 3/14/2024Total: $49,764.00 ($11.31/share)Vanguard Group Inc.Bought 494,173 shares on 3/11/2024Ownership: 2.996%Wellington Management Group LLPBought 80,688 shares on 3/5/2024Ownership: 0.162%Goldman Sachs Group Inc.Sold 40,384 shares on 3/1/2024Ownership: 0.182%American International Group Inc.Bought 2,600 shares on 2/28/2024Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions ALXO Stock Analysis - Frequently Asked Questions Should I buy or sell ALX Oncology stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALXO shares. View ALXO analyst ratings or view top-rated stocks. What is ALX Oncology's stock price target for 2024? 7 analysts have issued 12-month price targets for ALX Oncology's stock. Their ALXO share price targets range from $11.00 to $27.00. On average, they predict the company's stock price to reach $18.42 in the next year. This suggests a possible upside of 65.2% from the stock's current price. View analysts price targets for ALXO or view top-rated stocks among Wall Street analysts. How have ALXO shares performed in 2024? ALX Oncology's stock was trading at $14.89 on January 1st, 2024. Since then, ALXO shares have decreased by 25.1% and is now trading at $11.15. View the best growth stocks for 2024 here. Are investors shorting ALX Oncology? ALX Oncology saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 2,910,000 shares, a drop of 16.4% from the February 29th total of 3,480,000 shares. Based on an average daily trading volume, of 377,600 shares, the short-interest ratio is currently 7.7 days. Currently, 10.7% of the company's shares are short sold. View ALX Oncology's Short Interest. When is ALX Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ALXO earnings forecast. How were ALX Oncology's earnings last quarter? ALX Oncology Holdings Inc. (NASDAQ:ALXO) issued its quarterly earnings data on Thursday, March, 7th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.09. What other stocks do shareholders of ALX Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and When did ALX Oncology IPO? ALX Oncology (ALXO) raised $128 million in an IPO on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor acted as the underwriters for the IPO and LifeSci Capital was co-manager. Who are ALX Oncology's major shareholders? ALX Oncology's stock is owned by a number of institutional and retail investors. Top institutional investors include Vestal Point Capital LP (3.32%), Vanguard Group Inc. (3.02%), Vanguard Group Inc. (3.00%), Point72 Asset Management L.P. (1.83%), Price T Rowe Associates Inc. MD (1.09%) and Price T Rowe Associates Inc. MD (1.09%). Insiders that own company stock include Jason Lettmann, Jaume Pons, Lsv Associates, Llc, Peter S Garcia, Peter S Garcia, Shelly Pinto and Sophia Randolph. View institutional ownership trends. How do I buy shares of ALX Oncology? Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALXO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.